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Membrane interactions of tetradccupcptidc toxin mastoparan (MP) and analogucs (MP-3, MP-X and polisks MP). as indicated by inhibition of 
various enzymatic and cellular activities. wcrc investigated. MP-3 was found to bc the least active in inhibiting protein kinas.c C (PKC: activated 
by phosphatidylscrine vesicles. synaptosomal mcmbrancs or phorbol eslcr), synapcosomal membrane Na.K-ATPasc and prolifcrdcion and viability 
of leukemia HLGO cells. MP-3. however, was as u&c as others in inhibiting PKC activated by arachidonace monomersand pborbol ester binding. 
The unique propcrcics of MP-3, the [des-llc’-Asn’J- analoguc of MP. might bc rclaccd IO its low functional amphiphilicity compared to others and 
useful in further dclincating biological activities associated with or regulated by mcmbrancs, 
Mastoparan and unulo~ucs; Protein kinasc C: Na,K-ATPasc: HL60 cell 
1. lNTRODUCTlON 
MP, an amphiphilic tetradccapeptidc, is a wasp 
venom toxin shown to possess a variety of biological 
activities, such as activation of phospholipase A2 [I .3] 
and phospholipase C [3,4], dcgranulation of mast cells 
and release of histamine [I]. binding to calmodulin [S] 
and troponin C [G], and inhibition of calmodulin-dc- 
pendent enzymes [7,8]. More recently, MP has also been 
reported to catalyze nucleotide xchange on G proteins 
in a manner similar to that of receptors [9] and. like 
other membrane-active polypeptides, inhibit PKC, 
Na,K-ATPase (Na pump) and TPA-induced HL60 ccl1 
differentiation [El. Structure-activity relationship stud- 
ies [lo], with the use of various syntlletic MP analogucs. 
indicate that hydrophobicity or hydrophobic moment 
of the peptides is related to their potency or ability to 
stimulate GTPase of G proteins, although relative con- 
tribution of the two parameters i unclear. In the pres- 
ent studies, we examined effects of MP and some ana- 
logues on PKC (activated by various lipid colhctors). 
synaptosomal membrane Na,K-AT&e and HL60 cells 
in order to gain some insights into functional intcrac- 
tions of these amphiphilic polypeptidcs with mem- 
A/~bre~iu~iu/~s: MP. mastoparan: P-MP, polistcs mastopnran: TPA. 
12.O-tctradecanoylphorbol-13.O-acctatc: PDBu. phorbol 12.13-dibu- 
tyrate: PS. phosphatidylserinc: PKC. protein kinasc C: PKM. protein 
kinasc M; ET-IS-OCH>, I-O-octadccyl-2-O-methyl-glyccro-3.phos- 
phocholinc; IC,,,. concentration causing 50% inhibition. 
Crrr~c~.sf)r)llffcrf(,~~ ddtws: J.F. Kuo. Dcparcmcnt of Pharmacology. 
Emory University School of Mcdicinc. Atlanta. GA 30322. USA. Fax: 
(I) (104) 727.03G5. 
brdncs. We observed that the toxin analogues differen- 
tially modified several biochemical nd cellular parame- 
ter5. 
2. MATERIALS AND METHODS 
MPand ils anulogucs wcrc purchased from Peninsular Laboralorics 
(Belmont, CA); TPA was from LC Services (Wolburn, MA); [‘HIthy 
midinc and [y-“?P]ATP were from ICN Radi6chemicals (Irvine. CA); 
human lcukcmia cell line HL60 was from American Typ Culture 
Collection (Rockvillc, MD): media and supplies for cell cuhurc were 
from Gibco (Grand Island. NY); PS. arachidonatc. hisconc HI (Type 
III-S) and ouabain were from Sigma Chemical Co. (St. Louis, MO). 
PKC ijas purhicd from pig brain extracts as described [I I]; the 
cnzymc preparation was devoid of other contaminating protein kinasc 
activities. Type 1 (y). 11 @) and 111 (a) isoforms of PKC were prepared 
by hydroxyal?Gcc chromatography as dcscribcd by Huang cc al. [13]. 
PKC was assnycd under the standard conditions [&I I]. Briefly. the 
reaction mixtures (0.2 ml) contained 5 /mol of Tris-HCI (pH 7.5). 2 
pml of MgCI:. 2 pg of sonicatcd PS. 40 ,~g of histonc HI. either 0.8 
flmol of EGTA or 0.06 flmol of CuC12 (300,~M fmal concentration), 
I nmol of [$‘P]ATP (containing about 1x10” cpm). and appropriate 
amount 01’ ~hc CII~~IIIC. The reaction. started with [y-“?P]ATP, was 
carried out for 5 min at 30°C. PKC was also assayed under modified 
cunditions in which nruchidonatc ( I25yM). or rat brain synaptosomal 
mcmbr;lnc (2 gg protchU0.l nil). instead of PS. were us44 co aclivate 
the cnqw in ~bc prcscncc of 300 FM CnCIz. In some expcrimcnls, 
PKC W;IS itssayd under iI suboptimill condition in the prcscnce of I’S 
(2 yg/O.? ml) ~IU.I CaC12 (SO,uM) in order to maximize the net enzyme 
activity that wus spccilically stimulated by 32 nM TPA. PKM was 
prcparcd by cryptic diycscion of PKC and its PS/Ca2‘-indcpendcnt 
activity was assayed us dcscribcd [IS], Na.K-ATPasc was purified 
from rat ccrcbral cor’tcx sy~q~~so~~~us by extraction with sodium 
dodccyl sulfalc and discontinuous sucrose density cmcrifugation, as 
described [l-l-IG]. Mg-ATPusc activity in this mcmbranc prcparacion 
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(which was also used in PKC octivittion assay as an alternative phos- 
pholipid cot-actor as mcntioncd itbovc) \WS ICSS than 4% of the total 
ATPasc activity. Na.K-ATPasc activily wus assayed as described [lci], 
using 3 mM [$?P]ATP (containing 1 !-Xxll)‘cpm) to start he reaction, 
The activity ofall enzymes studied wcrc lincar us Y I’unction of incuba- 
tion time and enzyme amount under 111~’ cspcrimental conditions. All 
experiments concerning clTec~s ol’thc agents on the cnzymcs and HL60 
cells (see below) were repealed two lo t’oul’ LilllCs lo sscartain rcproduc- 
ibility of the findings reported herein. 
Bovine cardiac TnI and TnT. purilicd as rcportcd rcccnlly [171, were 
kindly provided by Dr. Thomas A. Noland 01’ this laboratory. 
[‘H]PDBu binding to PKC was carried out as reported [IS]. HL60 cells 
were cultured in RPM1 1640 medium supplrmrnted with IO% hcat- 
inactivated bovine calf serum. Cells at the mid-log phase were used in 
all experiments. [‘H]Thymidinc uptukc by the cells was detcrmincd as 
reported [IS]. 
3. RESULTS 
The structures of tetradecapeptide toxin MP and its 
analogues are shown (Table I). MP-3 is [des-Ilc’- 
A&IMP whereas MP-X and P-MP. compared to MP, 
have different sequences in 5 and 12 amino acid resi- 
dues, respectively. The hydrophobicities (H$) of the 
polypeptides hown in Table I were calculated using 
values of Kytes a.nd Doolittle [19] without correction of 
free N-terminal groups. 
Because PKC isozymes a, p and y were inhibited, 
with similar potencies, by MP (data not shown) and by 
other PKC inhibitors [S], the present PKC preparation, 
which had not been resolved into the individual 
isozymes and presumably amixture of all isoforms orig 
inally present in the pig brain extract, was used in all 
studies reported herein. The concentration-dependent 
inhibition by MP and its analogues of PKC activated 
by PS vesicles (Fig. 1A) or by rat brain synaptosomal 
membranes (Fig.. IB) showed that MP-3 was apprecia- 
bly less potent than others (MP, MP-X and P-MP). 
Such a difference in the inhibitory potency, however, 
was not observed when the enzyme was activated by 
arachidonate monomers (Fig. 1C). The dose-dependent 
inhibition of PSICaZ+-dependent PKC activity by ET- 
18-0CH3, an anticancer agent [8,20] was also included 
for comparison (Fig. 1A). The lCsO values estimated 
from these experiments were summarized (Table II). 
Histone Ml, a highly basic and cationic protein, was 
Table I 
Structures and average hydropathy (He) or mastoparan and ana- 
logucs 
Peptidc toxin Amino acid sequence 110 
Mastoparan (MP) IXLKALAAIsAKKfL 1.16 
Mastoparan 3 (MP-3) _____-__-__- 1.27 
Mastoparan X (MP-X) __r#q_G*__M___L_ 0.53 
Polistcs mastoparan (P-MP) VDW-KIGQSILSV- 0.35 
,--_. 
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Fig. 1. Inhibition of PKC by MP analogues and ET-18.OCHJ. The 
cnzymc was activated, in the presence of 200 pM CaCI:, by (A) PS 
vesicles (IO j&/ml), (B) rat brain synaptosomnl membrane (IO ,~g 
protein /ml) and (C) arachidonate monomers (I25 yM). The control 
activity values obtained in the absence of the inhibitors l-or (A), (B) 
and (C) were 13.8. 1 I ,9 and 14.4 pmol/min, respectively. which were 
taken as 100%. In this and subscqucnt figures, all data points pre- 
scnted were averages ofduplicate incubations, with assay errors being 
less than 5%; the results were conlirmcd in 2-4 other separate xpcri- 
mcnts. 
used as a standard substrate protein for PKC through- 
out the present studies. In order to ascertain that the 
findings reflected the true mode of inhibition of the 
toxins, bovine cardiac Tnl (PI = 9.5) and TnT (PI = 7.3) 
were used as substrates instead of histone HI in parallel 
experiments in which PKC was activated under stand- 
ard assay condition in the presence of PS and Ca” 
(figures not shown). The lCso values for MP and its 
analogues, also compared in Table II, clearly indicated 
that the peptide toxins had similar order of inhibitory 
potency regardless of the kinds of substrate proteins 
used. TnI and TnT have been shown previously to be 
excellent PKC substrates in various contractile protein 
preparations [17,21]. It was also noted that MP-3 was 
less potent han MP in inhibiting TPA-stimulated PKC 
activity (Table 11). 
Effects of MP and analogues on [“I-I]PDBu binding 
to PKC (in the presence of 2 ,@0.25 ml of PS and 20 
yM CaCl,) were examined. It was observed, unexpect- 
edly, that all agents inhibited the binding with similar 
I&, values of 2-3 yM (Fig. 2; Table II), despite the 
different potency of MP (?.C,, = 5,~uM) and MP-3 (ICso 
= 40 yM) in inhibiting TPA-stimulated PKC activity 
shown above in Table Il. ET-1%OCHJ was much less 
potent inhibitor for [%I]PDBu binding than MP and 
analogues (Fig. 2), consistent with its low potency in 
inhibiting TPA-stimulated PKC activity (Table II). 
We reported previously that MP and other amphi- 
philic protein toxins inhibited PKC competitively with 
respect o PS [S], indicating that they interacted with 
sites on the hydrophobic domain of the enzyme which 
wcrc also shared by PS. Consistent with the above no- 
tion, we observed that MP and MP-3 were practically 
without effect on the activity of PKM, the PS/Ca”- 
independent catalytic fragment of PKC, with an esti- 
mated I& value of >200 ,uM for both (Table II), 
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Na,K-ATPasc activity in the rat brain synaptosomal 
membrane in order to further illustrate a functional 
consequence of their interactions with a biomembrane. 
The same membrane preparation was used in the pres- 
ent (Fig. 1 B) and previous tudies [S] in PKC activation. 
Ouabain potently inhibited the activity, with an ICs, of 
about 1 PM; it inhibited about 80% of the activity at 100 
,uM, indicating that about 20% of the ATPase activity 
was ouabain-resistant (Fig. 3). Although less potent 
than ouabain and ET-lS-OCHJ, MP and its analogues 
inhibited Na,K-ATPase activity in the biomembrane, 
with MP-3, again, being the least effective (Fig. 3; Table 
II). 
Finally, membrane ffects of MP and its analogues 
were examined using intact HLGO cells. MP-3 was prac- 
tically inactive at the highest concentration (50 PM) 
tested, P-MP was moderately active, and MP and MP-X 
were most active in inhibiting proliferation (thymidine 
uptake) and in causing loss of viability of the leukemia 
cells (Table II). MP and its analogues consistently had 
higher IC,, values for causing viability loss than for 
inhibition of thymidine incorporation, suggesting that 
cell death due to cytotoxicity of the peptides might be 
secondary to impaired proliferation. 
Fig. 2. Inhibition of [JH]PDBu binding to DKC by MP analogucs and 
ET-IS-OCH>. The enzyme was incubated for 30 min at 37°C in the 
prcsencc or PS (2 p&O.?5 ml), CaClz (20 PM), [‘HIPDBu (32 nM, 
17.000 cpm). with or without non-radioactive PDBu (ZOO yM). and 
varying concentrations of the inhibitors, as indicated. The non-specific 
binding was less than 10% or the total binding. The specific binding 
(70 pmoUmg protein) obtained in the absence of the inhibitors was 
taken as 100%. 
4. DlSCUSSION 
The present studies howed that MP and analogues 
regulated PKC and other biological activities via com- 
plex and yet discrete interactions with membranes. Two 
points seem worth noting in this respect. First, MP-3, 
among the MP analogues, was the weakest inhibitor of 
PKC when it was activated by membranes (PS vesicles 
or synaptosomal membranes), but it was as effective as 
other inhibitors when the enzyme was activated by ara- 
chidonate monomers (see Table II for summary). Al- 
though each of these three lipid preparations activated 
PKC to a similar extent in the presence of Ca” (Fig. I), 
the physical interactions between the hydrophobic, reg- 
ulatory domain of PKC and the phospholipid mem- 
branes (PS and bio-membrane) would be distinct from 
those with the fatty acid (arachidonate) monomers. Ac- 
cordingly, interactions of the fatty acid with PKC could 
be relatively simplistic and could not afford complex, 
spatial arrangements hat would serve as determinants 
for specificity of inhibition. Strynadka and James [22], 
using MP and melittin as models, suggested that bind- 
ing of the amphiphilic helical peptides to hydrophobic 
August 1992 
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Table II 
Summary of I&, values for MP and analopucs of various parameters (taken from Fig. I-3 and other experiments) 
Parameter MP MP.3 Ml”-X P-MP ET-18-OCHI 
PKC 
Activated by PS 3 (8)“(2)h 25 (30)“(25)b 9 (3)“(2)h 3 6 
Activated by synaptosomal membrane 9 20 3 (9:(4)b 12’ 
Activated by arachidonate 5 6 6 8 l(i’ 
Activated by TPA 5 40 100 
[)H]PDBu binding 2 3 3 3 50 
PKM ~xtO’1 >lc@ 
Synaptosomal Na.K-ATPasc 60 -200 40 80 16 
H L60 cells 
[“HJThymidinc uptake 8 -50 7 IB 10 
Viability IO -700 10 25 13 
” PKC was assayed using bovine wsdiac Trill (instead or histonc HI) as substrate. 
“PKC was assayed using bovine casdiac TnT (instead of histonc Ill) as substrate 
‘Taken from [8]. 
“PKM tvas inhibited only about 10% at the highest concentration (IOOpM) tested. 
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Fig 3. Inhibition of rat brain synuptosomal nwnbrnnr Na,K-ATPasc 
by ouabain, ET-l &OCH, and MP analogucs. The membrane prepara~ 
tion ( IOyg protein/ml) was incubated for 30 min at 37°C with various 
concentrations of the inhibitors, as indicated. The standard reaction 
mixture contained 100 mM NaCI, 20 mM KCI. 4 mM MyC&, I mM 
EDTA and 3 mM [y-“?]ATP (2~10~ cpm). The control activity ob- 
tained in the absence of the inhibitors (9 pmol P rcleascd/minlmg 
protein) was taken as 100%. 
cleft of troponin C or calmodulin requires not only 
hydrophobic but also electrostatic nteractions. MP-3 is 
[des-Ile’-Asn’]MP, which lacks isoleucin-I and asparag- 
me-2 residues at the N-terminal of MP. Based upon 
helical wheel analysis [23], MP, MP-X and P-MP all 
have greater amphiphilicity than MP-3. It is likely, 
therefore, that MP-3 could not interact as effectively as 
other MP analogucs with hydrophobic cleft or domain 
on PKC unmasked by phospholipid membranes and 
Ca?‘, hence MP-3 was the weakest PKC inhibitor 
among MP analogues. The differential activity potency 
of MP analogues, MP-3 being the least active, was also 
evident in the inhibition of synaptosomal Na,K-ATPase 
and ML60 cell proliferation and viability (Table II), 
where biomembranes are involved. It was noted that 
alkllysophospholipid ET-IS-OCI-IJ inhibited PKC with 
a similar potency regardless of the kind of lipid cofac- 
tors being used to activate the enzyme (Table II), sug- 
gesting lack of rigid structural requirement, relative to 
peptide inhibitors, for its interaction with hydrophobic 
cleft (domain) of PKC. 
The second point to be discussed concerns the obser- 
vation that, while being as active as MP and other ana- 
logues in inhibiting [3H]PDBu binding to PKC/PS/Ca”+ 
complex, MP-3 was much less active than MP in inhib- 
iting TPA-stimulated PKC (Table II). One possible ex- 
planation for this discrepancy is that MP-3, the [dcs 
Ile’-Asn’] analogue, was able to selectively inhibit the 
binding more potently than the activation process ub- 
sequent o binding, consistent with the observation that 
MP-3 was also much less potent than MP in inhibiting 
PKC activity stimulated by PS/Ca’+ (Table II). Clearly, 
hydrophobic interactions of PKC with PS/Ca’+ was rc- 
quircd for action of MP-3 as in the case of MP, because 
both pcptides were practically inactive toward PKM. 
the catalytic domain of PKC devoid of the regulatory, 
hydrophobic domain (Table 11). Huang et al. [13] re- 
ported that phorbol ester binding and activation of 
PKC correlated well For the isozyme type I (y), but for 
isozymes type II (b) and III (3) its maximal binding 
failed to maximally activate the enzyme. The findings 
suggested that phorbol ester binding-activation is not 
necessary tightly coupled, lending support to the notion 
that the two events, although interrelated, could be dif- 
ferentiated by certain agents such as MP-3. In this re- 
spect, it is of interest hat defensins, the cationic peptide 
antibiotics produced by human neutrophils, potently 
inhibited PKC activated by PS/Cn?+ or by TPA (I&, 
I-2pM), but was inactive in inhibiting [3H]PDBu bind- 
ing to PKC (I&, >50 ,uM) [24]. In most cases, however, 
the pcptide PKC inhibitors, as ET-1%0CH3, inhibited 
equipotently both phorbol ester binding and activation 
of PKC; [8]. 
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